Asset
ZALIFRELIMAB
UROGEN PHARMA LTD. ORDINARY SHARES
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05375903 | phase1 | completed | 2022-06-01 | 2026-01-09 | UroGen Pharma Ltd. | A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) |
FDA applications (0)
This company has no applications containing this asset.